Literature DB >> 23653096

ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.

Raymond B Nagle1, Amit M Algotar, Connie C Cortez, Katherine Smith, Carol Jones, Ubaradka G Sathyanarayana, Steven Yun, Janice Riley, Dea Nagy, Ryan Dittamore, Bruce Dalkin, Laura Brosh, Gary Pestano.   

Abstract

BACKGROUND: This study examines the combined effect of two common genetic alterations, ERG and PTEN, in prostate carcinoma progression.
METHODS: Prostate tissue from 90 patients having unilateral capsular penetrating lesions, and a contra-lateral organ confined second lesion, were examined by immunohistochemistry for the expression of the TMPRSS2:ERG transformation product ERG and the loss of expression of PTEN, a powerful phosphatase inhibiting the PI3 kinase pathway. Multivariate logistic regression was carried out to analyze the data.
RESULTS: After adjusting for Gleason score, the odds of having capsular penetration were 5.19 times higher (P = 0.015) for ERG+/PTEN- group as compared to the wild type (ERG-/PTEN+).
CONCLUSIONS: This study presents the first evidence that ERG over expression and PTEN deletion is associated with greater risk of capsular penetration. Although further studies are needed, these results have the potential to change clinical assessment for prostate cancer.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23653096      PMCID: PMC4038303          DOI: 10.1002/pros.22675

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  30 in total

1.  Molecular classification of prostate cancer using curated expression signatures.

Authors:  Elke K Markert; Hideaki Mizuno; Alexei Vazquez; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

2.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Authors:  Jacques Lapointe; Young H Kim; Melinda A Miller; Chunde Li; Gulsah Kaygusuz; Matt van de Rijn; David G Huntsman; James D Brooks; Jonathan R Pollack
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

3.  TMPRSS2-ERG and PTEN loss in prostate cancer.

Authors:  Jeremy A Squire
Journal:  Nat Genet       Date:  2009-05       Impact factor: 38.330

4.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

Authors:  Rohit Mehra; Scott A Tomlins; Jianjun Yu; Xuhong Cao; Lei Wang; Anjana Menon; Mark A Rubin; Kenneth J Pienta; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

5.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

6.  TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Authors:  Andrew D Darnel; Christopher J Lafargue; Robin T Vollmer; Jacques Corcos; Tarek A Bismar
Journal:  Cancer Biol Ther       Date:  2009-02-04       Impact factor: 4.742

7.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

8.  Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis.

Authors:  Raymond B Nagle; Anne E Cress
Journal:  Prostate Cancer       Date:  2011-06-21

9.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Authors:  A H M Reid; G Attard; L Ambroisine; G Fisher; G Kovacs; D Brewer; J Clark; P Flohr; S Edwards; D M Berney; C S Foster; A Fletcher; W L Gerald; H Møller; V E Reuter; P T Scardino; J Cuzick; J S de Bono; C S Cooper
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

10.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

View more
  9 in total

Review 1.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

Review 2.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

3.  PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.

Authors:  Yue Wang; Bo Dai
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Authors:  Jacqueline Fontugne; Daniel Lee; Chiara Cantaloni; Christopher E Barbieri; Orazio Caffo; Esther Hanspeter; Guido Mazzoleni; Paolo Dalla Palma; Mark A Rubin; Giovanni Fellin; Juan Miguel Mosquera; Mattia Barbareschi; Francesca Demichelis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-10       Impact factor: 4.254

5.  ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.

Authors:  Amal Almami; Samar A Hegazy; Arash Nabbi; Mohammed Alshalalfa; Asma Salman; Hatem Abou-Ouf; Karl Riabowol; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-01-23

6.  Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.

Authors:  Lakshmi P Kunju; Shannon Carskadon; Javed Siddiqui; Scott A Tomlins; Arul M Chinnaiyan; Nallasivam Palanisamy
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-09

7.  Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.

Authors:  Sung Han Kim; Soo Hee Kim; Jae Young Joung; Geon Kook Lee; Eun Kyung Hong; Kyung Min Kang; Ami Yu; Byung Ho Nam; Jinsoo Chung; Ho Kyung Seo; Weon Seo Park; Kang Hyun Lee
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

8.  ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.

Authors:  Silvia Hernández-Llodrà; Nuria Juanpere; Silvia de Muga; Marta Lorenzo; Joan Gil; Alba Font-Tello; Laia Agell; Raquel Albero-González; Laura Segalés; José Merino; Laia Serrano; Lluís Fumadó; Lluís Cecchini; Josep Lloreta-Trull
Journal:  Oncotarget       Date:  2017-05-26

9.  Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.

Authors:  Byeong-Joo Noh; Ji-Youn Sung; Youn Wha Kim; Sung-Goo Chang; Yong-Koo Park
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.